The first gene therapy for muscular dystrophy has been approved for some kids

The Food and Drug Administration cleared the therapy for use in 4- and 5-year-olds, for now

A photo of a sign for the U.S. Department of Health and Human Services Food and Drug Administration.

The U.S. Food and Drug Administration has approved the first gene therapy for patients with Duchenne muscular dystrophy, a genetic disease that causes muscles to degenerate, eventually leading to death.

Sarah Silbiger/Getty Images

The first gene therapy for children with Duchenne muscular dystrophy has been approved by the U.S. Food and Drug Administration. The therapy can be used in 4- and 5-year-olds with the degenerative muscle disease, the agency announced June 22.

Duchenne muscular dystrophy, the most common form of the muscle disease, is caused by mutations in the dystrophin gene, which normally makes a large protein that acts as a shock absorber to keep muscle cells intact.

Patients with Duchenne muscular dystrophy don’t make this shock-absorbing protein and “damage themselves literally every time they contract their muscles,” Douglas Ingram, president and chief executive of Sarepta Therapeutics, the company that makes the newly approved gene therapy, said in a conference call discussing the approval.

The disease becomes fatal when heart muscles and muscles that control breathing also deteriorate. About 6 of every 100,000 people in Europe and North America has Duchenne muscular dystrophy. It mostly affects males.

The gene therapy is a shortened form of the dystrophin gene. This microdystrophin gene produces a protein about one-third the size of the original protein. The shortened gene is packed into harmless viruses for delivery to muscle cells. 

The therapy “is groundbreaking as it … is designed to target the underlying cause of the disease,” Sharon Hesterlee, chief research officer for the Muscular Dystrophy Association, said in a statement.

Three other companies —  PfizerGenethon and Solid Biosciences  — are also developing shortened dystrophin gene therapies to treat Duchenne muscular dystrophy.

Sarepta won approval by showing that children treated with the gene therapy make the shortened dystrophin protein. But Sarepta hasn’t yet completed an ongoing clinical trial to demonstrate whether the therapy actually works to restore muscle function. Results of that trial are expected this fall.

If the results are disappointing, the FDA or the company could decide to withdraw the therapy from the market. If the data show that the therapy is safe and effective, its use could be expanded to children and people of other ages.

Encouraging results might allow doctors to treat babies shortly after birth before their muscles are damaged, says Jerry Mendell, a neurologist at Nationwide Children’s Hospital in Columbus, Ohio. He helped develop the gene therapy and has been conducting the clinical trials sponsored by Sarepta, but said he has no financial stake in the company.

Even better gene therapy for muscular dystrophy is on the horizon, Mendell says. “What we’ve done now is open the window for treatment for muscular dystrophy, we haven’t closed it. This isn’t the end. You’re going to see many improvements as time goes on.”

Tina Hesman Saey is the senior staff writer and reports on molecular biology. She has a Ph.D. in molecular genetics from Washington University in St. Louis and a master’s degree in science journalism from Boston University.

More Stories from Science News on Genetics

From the Nature Index

Paid Content